{"meta":{"page":1,"per_page":50,"max_per_page":100,"total":19,"total_is_capped":false,"direct_labels_cover":0,"predictions_cover":19,"direct_label_status":"direct model label, unvalidated","prediction_status":"machine_predicted_unvalidated (Codex and Gemma teacher distillation)","score_status":"score_only:v0-immature-baseline (scores rank; they never assert a category)","snapshot":{"source":"OpenAlex, pinned release, all 482 partitions","release":"2026-06-24","frame_built":"2026-07-12"},"query_hash":"31c98ffb0e4d","filters":{"venue":"Liver Cancer"}},"results":[{"id":"W3173725877","doi":"10.1159/000513486","title":"Atezolizumab plus Bevacizumab versus Sorafenib in the Chinese Subpopulation with Unresectable Hepatocellular Carcinoma: Phase 3 Randomized, Open-Label IMbrave150 Study","year":2021,"lang":"en","type":"article","venue":"Liver Cancer","topic":"Hepatocellular Carcinoma Treatment and Prognosis","field":"Medicine","cited_by":129,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Roche (Canada)","funders":"","keywords":"Atezolizumab; Bevacizumab; Medicine; Internal medicine; Hazard ratio; Sorafenib; Hepatocellular carcinoma; Gastroenterology; Progression-free survival; Population; Phases of clinical research; Oncology; Clinical endpoint; Randomized controlled trial; Clinical trial; Confidence interval; Cancer; Chemotherapy; Nivolumab; Immunotherapy","retraction":null,"screen_n_in":null,"score":{"opus":0.1069567075284236,"gpt":0.3480448685584838,"spread":0.2410881610300601,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0006860938,0.0004438286,0.001094776,0.0001497026,0.0002382212,0.0002034376,0.0003714308,0.0001241354,0.0006463949],"category_scores_gemma":[0.00009243822,0.0002714293,0.0001512669,0.001098369,0.0001091857,0.0003217554,0.0001760726,0.0003734709,0.00003755495],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004828597,"about_ca_system_score_gemma":0.0007334634,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0123365,"about_ca_topic_score_gemma":0.005808264,"domain_scores_codex":[0.996838,0.0007000918,0.0005031849,0.0007164968,0.000721398,0.0005208093],"domain_scores_gemma":[0.9983559,0.000302805,0.000166574,0.0007746695,0.0002411227,0.0001589222],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.1838967,0.003451316,0.7974388,0.0001052855,0.0006155811,0.006540092,0.005354702,0.00001416501,0.000207348,0.0001069067,0.0001472088,0.002121892],"study_design_scores_gemma":[0.9267568,0.002145923,0.03388885,0.000136545,0.001947274,0.0001536729,0.001775904,0.03073858,0.001336831,0.00005362315,0.0005451157,0.0005208683],"study_design_candidate":"randomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9833558,0.008258672,0.00005148085,0.0006538001,0.0002613661,0.005240662,0.00003362652,0.0000435634,0.002101074],"genre_scores_gemma":[0.9959877,0.0003099088,0.0001776791,0.0002021245,0.0002180695,0.001686961,0.0002897823,0.00006218074,0.001065638],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.7635499,"threshold_uncertainty_score":0.9999738,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4310183164","doi":"10.1159/000528272","title":"IMbrave150: Efficacy and Safety of Atezolizumab plus Bevacizumab versus Sorafenib in Patients with Barcelona Clinic Liver Cancer Stage B Unresectable Hepatocellular Carcinoma: An Exploratory Analysis of the Phase III Study","year":2022,"lang":"en","type":"article","venue":"Liver Cancer","topic":"Hepatocellular Carcinoma Treatment and Prognosis","field":"Medicine","cited_by":76,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Roche (Canada)","funders":"Chugai Pharmaceutical; F. Hoffmann-La Roche","keywords":"Atezolizumab; Medicine; Sorafenib; Bevacizumab; Hepatocellular carcinoma; Response Evaluation Criteria in Solid Tumors; Internal medicine; Hazard ratio; Oncology; Liver cancer; Cancer; Phases of clinical research; Gastroenterology; Confidence interval; Chemotherapy; Nivolumab; Immunotherapy","retraction":null,"screen_n_in":null,"score":{"opus":0.06051174997819984,"gpt":0.2949862541609207,"spread":0.2344745041827209,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0003825921,0.0003653997,0.00107432,0.0004474192,0.000244396,0.00001326211,0.0002856311,0.00008259781,0.002347971],"category_scores_gemma":[0.00001637357,0.000275624,0.0002254698,0.001710092,0.0001969498,0.0001792714,0.0003113859,0.0003840993,0.000001276758],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007785041,"about_ca_system_score_gemma":0.0007180907,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.01198472,"about_ca_topic_score_gemma":0.004500629,"domain_scores_codex":[0.9967691,0.0005260417,0.0006911019,0.0006873324,0.0009025811,0.0004238725],"domain_scores_gemma":[0.9982269,0.0001425774,0.0004171583,0.0007977523,0.0002253859,0.000190227],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.03474547,0.00315811,0.9471153,0.0001190766,0.002356047,0.000142234,0.01027947,0.0003095561,0.00009696151,0.000006155665,0.00002100883,0.001650632],"study_design_scores_gemma":[0.08565446,0.005347112,0.8871734,0.00006406672,0.006353996,5.242619e-7,0.00298311,0.01082535,0.001066629,7.039721e-7,0.0001913229,0.0003393733],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9921583,0.004220078,0.000003869377,0.00002589839,0.0001584482,0.002687794,0.0006410755,0.00002082545,0.00008374594],"genre_scores_gemma":[0.9985758,0.0003034138,0.00001673639,0.00004680453,0.00003336736,0.0005048211,0.0001657326,0.00005238652,0.000300919],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.05994194,"threshold_uncertainty_score":0.9999696,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2559460526","doi":"10.1159/000449346","title":"Hepatocellular Carcinoma: The Role of Interventional Oncology","year":2016,"lang":"en","type":"review","venue":"Liver Cancer","topic":"Microbial Inactivation Methods","field":"Biochemistry, Genetics and Molecular Biology","cited_by":60,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Toronto General Hospital; Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Hepatocellular carcinoma; Medicine; Liver transplantation; Incidence (geometry); Surgical resection; Internal medicine; Oncology; Transplantation; General surgery","retraction":null,"screen_n_in":null,"score":{"opus":0.04764116408169632,"gpt":0.3697047981926722,"spread":0.3220636341109759,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002194318,0.0001743884,0.0004560569,0.00003633894,0.00003156449,0.000004698094,0.0003242675,0.0002957027,0.0006243443],"category_scores_gemma":[0.00003289149,0.0001037386,0.0004334342,0.00006273807,0.0001168382,0.000001588991,0.0001787489,0.0001258527,0.00002065628],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00008511147,"about_ca_system_score_gemma":0.0004076482,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00009017379,"about_ca_topic_score_gemma":0.00001272648,"domain_scores_codex":[0.9988663,0.0003472739,0.0003173808,0.0002615168,0.00007431503,0.0001331666],"domain_scores_gemma":[0.9991361,0.00004413911,0.0003655499,0.0003317389,0.00009386268,0.00002863951],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.00001219843,0.00003579844,0.00007390619,0.001011686,0.000202743,0.000001396071,0.00001408989,9.835491e-8,0.008889583,0.0003189231,0.002142192,0.9872974],"study_design_scores_gemma":[0.0000908515,0.00006915673,0.000007300598,0.0008561536,0.0001474341,0.00001201735,0.000005172823,0.000001163713,0.009349097,0.00004251213,0.9892987,0.0001204528],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.0001964939,0.9974464,0.0004512033,0.00001768591,0.0002776863,0.0002941189,0.0001643511,0.000002852891,0.001149164],"genre_scores_gemma":[0.0004501319,0.9963307,0.0002636623,0.00003782225,0.0005339829,0.0001299218,0.00007945372,0.00002747048,0.002146889],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.987177,"threshold_uncertainty_score":0.6836132,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4323307162","doi":"10.1159/000529996","title":"Albumin-Bilirubin Grade Analyses of Atezolizumab plus Bevacizumab versus Sorafenib in Patients with Unresectable Hepatocellular Carcinoma: A Post Hoc Analysis of the Phase III IMbrave150 Study","year":2023,"lang":"en","type":"article","venue":"Liver Cancer","topic":"Hepatocellular Carcinoma Treatment and Prognosis","field":"Medicine","cited_by":57,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Roche (Canada)","funders":"Chugai Pharmaceutical; F. Hoffmann-La Roche","keywords":"Bevacizumab; Medicine; Atezolizumab; Sorafenib; Internal medicine; Hepatocellular carcinoma; Liver function; Gastroenterology; Population; Post-hoc analysis; Oncology; Tolerability; Clinical endpoint; Surgery; Randomized controlled trial; Adverse effect; Cancer; Chemotherapy; Nivolumab","retraction":null,"screen_n_in":null,"score":{"opus":0.09168397289620757,"gpt":0.3275482401496349,"spread":0.2358642672534274,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002149375,0.0003577183,0.001151513,0.000907575,0.00009801365,0.00001571458,0.0002946681,0.0001100433,0.0002932459],"category_scores_gemma":[0.00003696513,0.0002375717,0.0004547224,0.004874063,0.0001632205,0.0001104836,0.000156504,0.000206168,0.000006681504],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004130697,"about_ca_system_score_gemma":0.0004216397,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.01803069,"about_ca_topic_score_gemma":0.003903497,"domain_scores_codex":[0.9971956,0.000208717,0.0006358304,0.0005623641,0.0009235664,0.0004739446],"domain_scores_gemma":[0.9982098,0.0001451163,0.0003329608,0.0008242902,0.0003477253,0.0001401601],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.01316637,0.001944463,0.9751662,0.0001228035,0.004339172,0.0002045936,0.00321587,0.0001882633,0.0009952849,0.00000492647,0.0000455123,0.0006065221],"study_design_scores_gemma":[0.05404129,0.004155851,0.8965807,0.0001035102,0.01154775,8.058176e-7,0.001324165,0.01710134,0.01482604,0.00000171205,0.00003371357,0.0002831545],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9961253,0.001356503,0.000002603258,0.00007284853,0.000113634,0.001950885,0.0002655359,0.00003550873,0.00007720209],"genre_scores_gemma":[0.9990663,0.00009141218,0.00001759287,0.00001973567,0.00002834502,0.0002022476,0.000276749,0.00004292318,0.0002547141],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.07858555,"threshold_uncertainty_score":0.9885083,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W3185994964","doi":"10.1159/000516490","title":"Baseline Liver Function and Subsequent Outcomes in the Phase 3 REFLECT Study of Patients with Unresectable Hepatocellular Carcinoma","year":2021,"lang":"en","type":"article","venue":"Liver Cancer","topic":"Hepatocellular Carcinoma Treatment and Prognosis","field":"Medicine","cited_by":51,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"BC Cancer Agency","funders":"Eisai","keywords":"Lenvatinib; Sorafenib; Medicine; Hepatocellular carcinoma; Internal medicine; Liver function; Adverse effect; Oncology; Overall survival; Post-hoc analysis; Gastroenterology","retraction":null,"screen_n_in":null,"score":{"opus":0.05933619209472887,"gpt":0.2809289060137234,"spread":0.2215927139189945,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001999582,0.0001763826,0.0003445513,0.00008761208,0.00006033813,0.00001757123,0.00005675741,0.00005042249,0.0003218474],"category_scores_gemma":[0.0000200733,0.0001069983,0.00005573958,0.0003409138,0.00003834174,0.00008599725,0.0000346601,0.0001409876,0.000002876838],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00008595066,"about_ca_system_score_gemma":0.0001125154,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002354113,"about_ca_topic_score_gemma":0.001248494,"domain_scores_codex":[0.9986406,0.0002119358,0.0002301308,0.0003129908,0.0004033083,0.0002010142],"domain_scores_gemma":[0.9992771,0.00008309575,0.00007504565,0.0003090469,0.0001887999,0.00006689504],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.000944351,0.00319348,0.9907148,0.00009654256,0.0001924235,0.0005784102,0.00175229,9.872749e-7,0.0002352883,0.000008996399,0.00006302114,0.002219392],"study_design_scores_gemma":[0.01200914,0.002528037,0.9804742,0.00005242986,0.0006707045,0.000005502026,0.0007008342,0.001114412,0.001913229,0.000004463474,0.0004022341,0.000124777],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9947729,0.003773143,0.00002145491,0.0001286817,0.00005634088,0.001096438,0.00003205083,0.00001173548,0.0001072537],"genre_scores_gemma":[0.9990334,0.0001555762,0.00004648205,0.0002234913,0.00003860586,0.0001742208,0.00008576921,0.00001898396,0.0002234643],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.01106479,"threshold_uncertainty_score":0.4363265,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4320717208","doi":"10.1159/000529636","title":"Pembrolizumab as Second-Line Therapy for Advanced Hepatocellular Carcinoma: Longer Term Follow-Up from the Phase 3 KEYNOTE-240 Trial","year":2023,"lang":"en","type":"article","venue":"Liver Cancer","topic":"Hepatocellular Carcinoma Treatment and Prognosis","field":"Medicine","cited_by":46,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"Bayer Yakuhin; Chugai Pharmaceutical; Sirtex Medical; Ipsen; Servier; Ono Pharmaceutical; Eisai; Sanofi; Bayer HealthCare; Incyte; EA Pharma Co., Ltd.; Gilead Sciences; Amgen; Pfizer; Celgene; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Pembrolizumab; Medicine; Hepatocellular carcinoma; Term (time); Oncology; Internal medicine; Cancer; Immunotherapy; Physics","retraction":null,"screen_n_in":null,"score":{"opus":0.09416067897063918,"gpt":0.321198574962859,"spread":0.2270378959922199,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0002198867,0.0004422525,0.0006472695,0.00010975,0.0002792226,0.00005982177,0.0002652819,0.0002158599,0.003396897],"category_scores_gemma":[0.00005471604,0.0003033414,0.0006295028,0.0004027647,0.0001012822,0.0001521539,0.00006404699,0.0002605414,0.000285836],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001777361,"about_ca_system_score_gemma":0.0003713597,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0005900247,"about_ca_topic_score_gemma":0.0001130088,"domain_scores_codex":[0.997686,0.000102708,0.0004400023,0.0007049253,0.0004334263,0.0006329214],"domain_scores_gemma":[0.9983451,0.0003789279,0.0001615574,0.0007099747,0.0001673889,0.0002370744],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.3254165,0.001397718,0.4149203,0.0002314455,0.002115268,0.001500746,0.008445764,0.000002699364,0.03517129,0.00009977371,0.02827945,0.1824191],"study_design_scores_gemma":[0.6432809,0.008317336,0.02487554,0.0002345383,0.001885175,0.00002618162,0.0004844099,0.01046233,0.1474977,0.0005207674,0.16125,0.001165257],"study_design_candidate":"randomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9813149,0.0102326,0.00006041893,0.001236211,0.001576179,0.004447715,0.0006154815,0.0002226043,0.0002938964],"genre_scores_gemma":[0.982091,0.001605717,0.00009083009,0.001242616,0.001956193,0.002495089,0.001045225,0.0001148358,0.009358548],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.3900448,"threshold_uncertainty_score":0.9999419,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4303470808","doi":"10.1159/000527403","title":"Regorafenib versus Cabozantinib as a Second-Line Treatment for Advanced Hepatocellular Carcinoma: An Anchored Matching-Adjusted Indirect Comparison of Efficacy and Safety","year":2022,"lang":"en","type":"article","venue":"Liver Cancer","topic":"Hepatocellular Carcinoma Treatment and Prognosis","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"EVRAZ (Canada)","funders":"European Commission; European Federation of Pharmaceutical Industries and Associations; University of Pittsburgh","keywords":"Regorafenib; Cabozantinib; Discontinuation; Medicine; Hepatocellular carcinoma; Sorafenib; Hazard ratio; Propensity score matching; Adverse effect; Internal medicine; Oncology; Surgery; Confidence interval; Cancer; Colorectal cancer","retraction":null,"screen_n_in":null,"score":{"opus":0.1111477898344688,"gpt":0.3278793606080632,"spread":0.2167315707735943,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0001649486,0.0003626828,0.0009258218,0.0001732078,0.0003171675,0.00001551073,0.0001192627,0.0001005448,0.0009387053],"category_scores_gemma":[0.00001836228,0.0003346608,0.0002120334,0.000301007,0.00008253572,0.0001080107,0.00008116035,0.0001924043,0.000003282445],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000387883,"about_ca_system_score_gemma":0.0002974969,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00127139,"about_ca_topic_score_gemma":0.000363354,"domain_scores_codex":[0.9980012,0.0001456033,0.000493449,0.0006204066,0.0003294748,0.0004098244],"domain_scores_gemma":[0.9987333,0.0001982686,0.000270412,0.0004330508,0.0001143289,0.0002506519],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.04211109,0.002511835,0.8599302,0.0004739705,0.001175917,0.0002966733,0.01156539,0.0001322382,0.01457082,0.0001934287,0.0002604853,0.066778],"study_design_scores_gemma":[0.2007279,0.06328855,0.2291334,0.0003549017,0.007851165,0.0001672224,0.007638796,0.06017115,0.3068607,0.00009703803,0.1214314,0.002277803],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9839706,0.01193195,0.00003283628,0.0001883681,0.0003509762,0.002614448,0.0005194049,0.00008193473,0.0003094541],"genre_scores_gemma":[0.9959449,0.0003327676,0.0008442063,0.00006666062,0.0001477109,0.000903168,0.0007621344,0.00006881211,0.0009296269],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.6307968,"threshold_uncertainty_score":0.9999745,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4303470795","doi":"10.1159/000526899","title":"PD-1/CTLA-4 Blockade Leads to Expansion of CD8+PD-1int TILs and Results in Tumor Remission in Experimental Liver Cancer","year":2022,"lang":"en","type":"article","venue":"Liver Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"","funders":"Medizinischen Hochschule Hannover; Deutsche Forschungsgemeinschaft; Government of Canada; Wilhelm Sander-Stiftung","keywords":"Blockade; CD8; Cytotoxic T cell; Medicine; Cancer research; Priming (agriculture); Tumor-infiltrating lymphocytes; Tumor microenvironment; Immunology; Nivolumab; Immunotherapy; Immune system; Biology; Internal medicine; Receptor","retraction":null,"screen_n_in":null,"score":{"opus":0.02389854169721906,"gpt":0.3067304720411475,"spread":0.2828319303439285,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0002975774,0.0001934678,0.0003689573,0.0002590363,0.0000699347,0.000008135866,0.0001178719,0.00005824786,0.001523327],"category_scores_gemma":[0.00001870261,0.0001789425,0.00006976684,0.0004858256,0.00007638489,0.00007677013,0.0001653087,0.0002626131,0.000002338101],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001008192,"about_ca_system_score_gemma":0.0002957127,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.01774531,"about_ca_topic_score_gemma":0.001235024,"domain_scores_codex":[0.9982476,0.00008691143,0.0004924155,0.0004633188,0.0004020629,0.0003077492],"domain_scores_gemma":[0.9994091,0.00004072884,0.0001349734,0.000260079,0.0000368849,0.0001182305],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.01733614,0.0002758131,0.01699917,0.0001226357,0.00003763815,0.0002182777,0.01017483,0.0001728625,0.9287466,0.000003601172,0.005103945,0.02080851],"study_design_scores_gemma":[0.01107655,0.00121108,0.1567268,0.001278609,0.00004559633,0.00005065475,0.002409215,0.0006341613,0.7847086,0.000004003918,0.04142551,0.0004292065],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9775926,0.01976631,0.000001276046,0.001053397,0.0003269369,0.0006413017,0.00008545373,0.00001920315,0.0005134509],"genre_scores_gemma":[0.994629,0.0019633,0.0001242865,0.001320902,0.0001122347,0.0003198311,0.00001232761,0.00002789119,0.001490239],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.144038,"threshold_uncertainty_score":0.9993894,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4388621275","doi":"10.1159/000534303","title":"Second-Line Treatment after Failure of Immune Checkpoint Inhibitors in Hepatocellular Carcinoma: Tyrosine Kinase Inhibitor, Retrial of Immunotherapy, or Locoregional Therapy?","year":2023,"lang":"en","type":"article","venue":"Liver Cancer","topic":"Hepatocellular Carcinoma Treatment and Prognosis","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"University of Calgary","funders":"","keywords":"Medicine; Hepatocellular carcinoma; Internal medicine; Oncology; Bevacizumab; Atezolizumab; Nivolumab; Adverse effect; Immunotherapy; Gastroenterology; Cancer; Chemotherapy","retraction":null,"screen_n_in":null,"score":{"opus":0.05778974049913274,"gpt":0.2666817629775639,"spread":0.2088920224784312,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0002624538,0.0004260118,0.0009505245,0.0004841353,0.00003922767,0.00001067251,0.0001180859,0.0002542975,0.00240563],"category_scores_gemma":[0.0000167231,0.0003068399,0.0005644137,0.001058313,0.0001859275,0.0001076953,0.00005822553,0.0001932885,0.0000246866],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003725423,"about_ca_system_score_gemma":0.0004522465,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002333048,"about_ca_topic_score_gemma":0.0004622149,"domain_scores_codex":[0.9975601,0.0001071847,0.0009773202,0.0004748376,0.0004440601,0.0004364384],"domain_scores_gemma":[0.9988025,0.0000885804,0.0003017554,0.0005045698,0.0001749373,0.0001275996],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.009757154,0.0008970641,0.8268126,0.0002872036,0.0003832896,0.001019862,0.002027643,0.000003203781,0.1494666,0.00000945096,0.0002592227,0.0090767],"study_design_scores_gemma":[0.01755902,0.003074773,0.1780502,0.0006985008,0.0001635906,0.00002077045,0.0001683678,0.000838878,0.793117,0.00002002744,0.005943901,0.0003449863],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9736761,0.02366957,0.000003164467,0.0004791569,0.0003147325,0.001567028,0.0001795774,0.00005428861,0.00005637171],"genre_scores_gemma":[0.9925082,0.00466307,0.0001346595,0.00005830297,0.0004465631,0.0005841372,0.0001860188,0.00007718821,0.001341862],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.6487625,"threshold_uncertainty_score":0.9999384,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4392015401","doi":"10.1159/000537966","title":"Tislelizumab versus Sorafenib in First-Line Treatment of Unresectable Hepatocellular Carcinoma: Impact on Health-Related Quality of Life in RATIONALE-301 Study","year":2024,"lang":"en","type":"article","venue":"Liver Cancer","topic":"Hepatocellular Carcinoma Treatment and Prognosis","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Princess Margaret Cancer Centre; Toronto General Hospital","funders":"National Cancer Institute; BeiGene","keywords":"Sorafenib; Hepatocellular carcinoma; Medicine; Quality of life (healthcare); Internal medicine; Oncology; Carcinoma","retraction":null,"screen_n_in":null,"score":{"opus":0.1663480367441998,"gpt":0.3602734384689181,"spread":0.1939254017247184,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003555431,0.0002883528,0.0009632194,0.0004064882,0.00003359043,0.00001026556,0.0000714333,0.0001145207,0.0007010656],"category_scores_gemma":[0.0000423355,0.0002215517,0.0002523132,0.0007613647,0.00005003106,0.00008180305,0.00002207997,0.0001601611,0.00001941259],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001435398,"about_ca_system_score_gemma":0.0009592182,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0858881,"about_ca_topic_score_gemma":0.01024503,"domain_scores_codex":[0.9976357,0.0002509823,0.0009259386,0.0004427444,0.0004131933,0.0003315063],"domain_scores_gemma":[0.9989222,0.0003355535,0.0001673953,0.0003405458,0.00007607088,0.0001582524],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.005740613,0.003050892,0.9810784,0.0004892806,0.0004981208,0.0003973901,0.004711199,0.0002609194,0.0001222311,0.00006863594,0.0001040576,0.003478253],"study_design_scores_gemma":[0.02686087,0.01209174,0.9356171,0.0005515221,0.0002535985,0.000003750742,0.0004674291,0.02129673,0.002332692,0.0000388589,0.0002153717,0.0002703601],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9605668,0.03606784,0.000002957267,0.0006202271,0.000215801,0.002141004,0.000144127,0.00002994935,0.0002113514],"genre_scores_gemma":[0.9976474,0.001504713,0.00002004629,0.00001884473,0.00006471422,0.0003141083,0.0001261425,0.00003373148,0.0002702859],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.07564307,"threshold_uncertainty_score":0.920199,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4392151488","doi":"10.1159/000537947","title":"Characterization of Tumor Responses in Patients with Unresectable Hepatocellular Carcinoma Treated with Lenvatinib in the Phase 3 Randomized Trial: REFLECT","year":2024,"lang":"en","type":"article","venue":"Liver Cancer","topic":"Hepatocellular Carcinoma Treatment and Prognosis","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Princess Margaret Cancer Centre","funders":"Chugai Pharmaceutical; Genentech; Ipsen; Astellas Pharma; Eisai; Plexxikon; Seagen; Pfizer; NuCana; Incyte; BeiGene; Clovis Oncology; Les Laboratories Pierre Fabre; EA Pharma Co., Ltd.; Merck KGaA; Baxalta; Sirtex Medical; Cancer Research UK; Boston Scientific Corporation; Halozyme; Exelixis; Sanofi; GlaxoSmithKline; Amgen; Celgene; Daiichi Sankyo Europe; National Cancer Institute; Servier; Bayer; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Lenvatinib; Medicine; Sorafenib; Hepatocellular carcinoma; Response Evaluation Criteria in Solid Tumors; Oncology; Internal medicine; Randomized controlled trial; Overall survival; Radiology; Clinical trial; Phases of clinical research","retraction":null,"screen_n_in":null,"score":{"opus":0.04313391345594417,"gpt":0.2807608521821021,"spread":0.2376269387261579,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005065583,0.0002142141,0.0006172727,0.0003122234,0.00002970351,0.00003314916,0.00008262148,0.0000571045,0.0001659673],"category_scores_gemma":[0.00004060847,0.000112824,0.00009080848,0.0008856495,0.00009459822,0.0001408228,0.00001128649,0.0001698434,0.00000366133],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001315061,"about_ca_system_score_gemma":0.0002704867,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001596232,"about_ca_topic_score_gemma":0.0001270162,"domain_scores_codex":[0.9982491,0.0004516082,0.0003781946,0.0003123634,0.0003755065,0.0002332448],"domain_scores_gemma":[0.9992623,0.0002499085,0.0001072196,0.0002435034,0.00009179506,0.00004525173],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.4606043,0.0004215738,0.5351844,0.0001229177,0.00009619472,0.0003725279,0.0009811147,2.451095e-7,0.001652499,0.00001277315,0.000008497802,0.0005429397],"study_design_scores_gemma":[0.8448542,0.003556732,0.120804,0.0009227816,0.0006296606,0.000007695547,0.00005620738,0.003273163,0.02529629,0.000004262873,0.000387391,0.0002075837],"study_design_candidate":"randomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9943978,0.001056145,0.00001460421,0.0001766647,0.00004367347,0.0040179,0.00006513738,0.00003158375,0.0001965531],"genre_scores_gemma":[0.9980798,0.00009945847,0.00003806967,0.00009899084,0.00005149013,0.001022208,0.0002567022,0.00003629804,0.0003170159],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.4143805,"threshold_uncertainty_score":0.4600829,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4401410496","doi":"10.1159/000540290","title":"Neratinib Alone or in Combination with Immune Checkpoint Inhibitors with or without Mammalian Target of Rapamycin Inhibitors in Patients with Fibrolamellar Carcinoma","year":2024,"lang":"en","type":"article","venue":"Liver Cancer","topic":"PI3K/AKT/mTOR signaling in cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":4,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Sudbury Regional Hospital","funders":"National Cancer Institute; University of California, San Francisco; University of Texas MD Anderson Cancer Center; Puma Biotechnology; Memorial Sloan-Kettering Cancer Center","keywords":"Neratinib; Medicine; Sunitinib; Everolimus; Axitinib; Tyrosine-kinase inhibitor; Nivolumab; Pembrolizumab; Internal medicine; Clinical endpoint; Oncology; Cancer; Immunotherapy; Clinical trial; Breast cancer","retraction":null,"screen_n_in":null,"score":{"opus":0.007036782436839323,"gpt":0.2275670107357827,"spread":0.2205302282989434,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001874221,0.0003313065,0.000399696,0.0001809046,0.00003572641,0.00003785462,0.0001651448,0.0001783903,0.0001077844],"category_scores_gemma":[0.00001583065,0.0002125678,0.00004802055,0.0005704858,0.0001685002,0.00003162707,0.00006098829,0.0002418068,0.000002067366],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001798742,"about_ca_system_score_gemma":0.0005852869,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0009985995,"about_ca_topic_score_gemma":0.002914813,"domain_scores_codex":[0.9981284,0.00008827449,0.0004648513,0.0005878172,0.0003769729,0.0003536859],"domain_scores_gemma":[0.9992307,0.00001998004,0.0001849153,0.0003299739,0.0001589634,0.00007540746],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.009629192,0.0003281342,0.9244326,0.0004787717,0.0001660857,0.00009325593,0.001373848,0.001467045,0.0602423,0.000007485384,0.0004049185,0.001376373],"study_design_scores_gemma":[0.01001517,0.006575644,0.1805699,0.001801432,0.00008401485,0.00001306491,0.0002979772,0.0006178651,0.7967381,0.000005542595,0.002514608,0.0007667459],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9967583,0.001947418,0.0001128389,0.0000963175,0.0001981341,0.0007225426,0.00006028619,0.0000192751,0.00008486444],"genre_scores_gemma":[0.9975799,0.00006890468,0.001240334,0.00006960653,0.00014739,0.0001660827,0.0001298509,0.00008091691,0.0005169643],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.7438627,"threshold_uncertainty_score":0.8668265,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4417466987","doi":"10.1159/000549955","title":"Early Safety Results from the Phase 3b SIERRA Study of Durvalumab and Tremelimumab as First-Line Treatment for Participants with Unresectable Hepatocellular Carcinoma and a Poor Prognosis","year":2025,"lang":"en","type":"article","venue":"Liver Cancer","topic":"Hepatocellular Carcinoma Treatment and Prognosis","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"AstraZeneca (Canada)","funders":"AstraZeneca","keywords":"Durvalumab; Tremelimumab; Hepatocellular carcinoma; Phases of clinical research; Ramucirumab; Chemoradiotherapy; Carcinoma","retraction":null,"screen_n_in":null,"score":{"opus":0.09119294205123218,"gpt":0.3126555805677392,"spread":0.221462638516507,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002030261,0.0003273427,0.000627781,0.00008266926,0.000265777,0.00004446017,0.00009205862,0.00009028929,0.00004813815],"category_scores_gemma":[0.000058241,0.0001969238,0.00009479438,0.0002785103,0.00012839,0.00008447171,0.00006012235,0.00009412164,0.000001460187],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001605568,"about_ca_system_score_gemma":0.0002473677,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.03032082,"about_ca_topic_score_gemma":0.004225269,"domain_scores_codex":[0.9981744,0.0001038022,0.0004437734,0.0006124702,0.0002732048,0.0003924069],"domain_scores_gemma":[0.9987043,0.0004307927,0.0001504298,0.0003841407,0.0001638105,0.0001666012],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.01994115,0.002370124,0.9506425,0.0001141426,0.001475258,0.0001349787,0.00816974,0.000002494801,0.0003170493,0.00001363954,0.0001281238,0.01669078],"study_design_scores_gemma":[0.1488496,0.03310804,0.7462116,0.000903033,0.01030821,0.0000121085,0.003221436,0.02077254,0.03094919,0.00006416881,0.005056921,0.0005432209],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9852231,0.007714768,0.00002417537,0.001436212,0.0000535673,0.00481498,0.0005688763,0.00003245966,0.0001318401],"genre_scores_gemma":[0.9963387,0.0009833388,0.0001294169,0.0001145513,0.00008425508,0.001452063,0.00009002828,0.00003200841,0.0007756401],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.2044309,"threshold_uncertainty_score":0.9761364,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W3139664658","doi":"10.36255/exonpublications.livercancer.2021.ch4","title":"Gross Dissection of Liver for Hepatocellular Carcinoma Using AJCC Cancer Staging Manual 8th Edition: Anatomical and Practical Considerations","year":2021,"lang":"en","type":"book-chapter","venue":"Liver Cancer","topic":"Congenital Heart Disease Studies","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Stollery Children's Hospital; University of Alberta; University of Alberta Hospital","funders":"","keywords":"Dissection (medical); Hepatocellular carcinoma; Medicine; Liver cancer; Cancer; General surgery; Terminology; Resection; Pathology; Radiology; Surgery; Internal medicine","retraction":null,"screen_n_in":null,"score":{"opus":0.07437325643932621,"gpt":0.348629559974269,"spread":0.2742563035349428,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00006724433,0.0003095963,0.0006227596,0.0001210417,0.0002181433,0.00003162289,0.00001648342,0.0002227859,0.001563445],"category_scores_gemma":[0.00005479429,0.0003208227,0.0002078927,0.00003837971,0.0003108382,0.0001465921,0.0001007549,0.000318984,0.000002149862],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003877948,"about_ca_system_score_gemma":0.0008397869,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0006163162,"about_ca_topic_score_gemma":0.00073006,"domain_scores_codex":[0.9985079,0.00002278714,0.0003668815,0.0005181197,0.0003363932,0.0002478846],"domain_scores_gemma":[0.9986308,0.0002161232,0.0001469737,0.0002130121,0.0006124257,0.00018064],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.01166375,0.002182259,0.4113081,0.05044064,0.02428586,0.03203464,0.01605817,0.00006455136,0.02551669,0.262928,0.1187355,0.04478187],"study_design_scores_gemma":[0.03705126,0.003995644,0.2694303,0.03211471,0.08303236,0.01082511,0.006725173,0.2291786,0.03911674,0.02195286,0.2538783,0.01269889],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.8966348,0.08131549,0.0011717,0.001836592,0.002453363,0.003730327,0.005159743,0.0001157157,0.007582309],"genre_scores_gemma":[0.9739145,0.003107921,0.0009983642,0.000350059,0.002185237,0.0001883357,0.0001264014,0.00009324333,0.01903593],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.2409751,"threshold_uncertainty_score":0.9999244,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4249856389","doi":"10.36255/exonpublications.livercancer.2021.pr","title":"Preface","year":2021,"lang":"en","type":"book-chapter","venue":"Liver Cancer","topic":"Hepatocellular Carcinoma Treatment and Prognosis","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"University of Alberta; Stollery Children's Hospital","funders":"","keywords":"Medicine; Hepatocellular carcinoma; Etiology; Fatty liver; Cancer; Liver cancer; Disease; Pathology; Internal medicine","retraction":null,"screen_n_in":null,"score":{"opus":0.09531691578801603,"gpt":0.261330717019093,"spread":0.166013801231077,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00002562675,0.0002608899,0.0004158666,0.00005744549,0.00003519056,0.00001514049,0.00005134464,0.0002924455,0.02251088],"category_scores_gemma":[0.000003119917,0.0002298236,0.0002830045,0.00002036871,0.00004149002,0.0000250225,0.00004816296,0.0002661342,0.0005478998],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001838253,"about_ca_system_score_gemma":0.0002733833,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00009097435,"about_ca_topic_score_gemma":0.00004442666,"domain_scores_codex":[0.9990641,0.00000685699,0.000152628,0.0003577868,0.0002464285,0.0001721346],"domain_scores_gemma":[0.9993424,0.00001791845,0.00006812417,0.0003321543,0.0001046588,0.0001347567],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0006406206,0.00035435,0.1801278,0.003569712,0.008646307,0.02397907,0.001504664,0.000001006167,0.0008974964,0.07110573,0.2451138,0.4640595],"study_design_scores_gemma":[0.0005276735,0.00009375907,0.0007230653,0.0006954758,0.001094432,0.0000390198,0.000003112871,0.00002792642,0.001025222,0.0001209549,0.9954045,0.0002448075],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"other","genre_gemma":"other","genre_scores_codex":[0.001690576,0.0821857,0.000006162064,0.0005195708,0.0003384204,0.0004732202,0.00008380038,0.00007266873,0.9146299],"genre_scores_gemma":[0.01690275,0.01081875,0.0001950119,0.000594641,0.0006574086,0.0000550763,0.0002004588,0.00007393091,0.970502],"genre_candidate":"other","genre_consensus":"other","teacher_disagreement_score":0.7502908,"threshold_uncertainty_score":0.9783826,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2131550821","doi":"10.1007/978-1-4020-9804-8_5","title":"Selection of Patients for Resection of Hepatic Colorectal Metastases: 18F-Fluorodeoxyglucose/Positron Emission Tomography","year":2009,"lang":"en","type":"book-chapter","venue":"Liver Cancer","topic":"Hepatocellular Carcinoma Treatment and Prognosis","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Ottawa Regional Cancer Foundation","funders":"","keywords":"Medicine; Positron emission tomography; Colorectal cancer; Radiology; Fluorodeoxyglucose; Stage (stratigraphy); Cancer; Internal medicine","retraction":null,"screen_n_in":null,"score":{"opus":0.03014802831968243,"gpt":0.2518629784872493,"spread":0.2217149501675669,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0001098591,0.0003233602,0.0007163872,0.000365396,0.00006119083,0.000005843457,0.00006366387,0.0002703597,0.0003482848],"category_scores_gemma":[0.00001637113,0.0002858519,0.000548175,0.0001137261,0.00006132218,0.00007000852,0.00001891235,0.0001813288,0.000002509192],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002366356,"about_ca_system_score_gemma":0.0001495111,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0002300193,"about_ca_topic_score_gemma":0.00007914462,"domain_scores_codex":[0.9985079,0.00003188277,0.0004829557,0.0003747194,0.0003991407,0.000203379],"domain_scores_gemma":[0.9986594,0.0000639261,0.0004695046,0.0001847438,0.0005173045,0.0001050836],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.0178747,0.001735049,0.7048594,0.00603686,0.004904547,0.00002617157,0.0007344247,0.000003683933,0.02670072,0.000820406,0.012174,0.2241301],"study_design_scores_gemma":[0.01122666,0.02879383,0.05417538,0.004892489,0.01453164,0.00001663688,0.00001880195,0.00137222,0.814787,0.001275316,0.06769733,0.001212652],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9485987,0.0122331,0.0001422239,0.00005229963,0.0005594161,0.005723504,0.001244411,0.00009794316,0.03134842],"genre_scores_gemma":[0.9747331,0.001728113,0.0007887264,0.00003617791,0.0002035951,0.0001696833,0.001028824,0.00007254903,0.02123923],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.7880863,"threshold_uncertainty_score":0.9999593,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4404467870","doi":"10.1159/000542146","title":"Acknowledgement to Reviewers","year":2024,"lang":"en","type":"article","venue":"Liver Cancer","topic":"Hepatocellular Carcinoma Treatment and Prognosis","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":false,"ca_fund":false,"ca_venue":false,"about_ca":true},"ca_institutions":"","funders":"","keywords":"Acknowledgement; Medicine; Computer science; Computer security","retraction":null,"screen_n_in":null,"score":{"opus":0.09618991736786028,"gpt":0.3242552020021041,"spread":0.2280652846342438,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00006313445,0.00008311232,0.0001287094,0.00006254866,0.00002036064,0.00002076019,0.00003229163,0.00002695483,0.004346195],"category_scores_gemma":[0.000008696672,0.00006378171,0.00009495617,0.0002101424,0.00000987777,0.00003220679,0.00002334364,0.00005736375,0.003179204],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001443578,"about_ca_system_score_gemma":0.00007531496,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00005465946,"about_ca_topic_score_gemma":0.00001947919,"domain_scores_codex":[0.9994496,0.00001102642,0.00008722932,0.0001928171,0.0001213962,0.0001379689],"domain_scores_gemma":[0.9996781,0.00001183071,0.000005621206,0.0001356397,0.0000453155,0.0001235114],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.00004564723,0.0000633328,0.1297666,0.0009850139,0.0003128416,0.0005596966,0.001099341,3.708168e-7,0.0009084872,0.0004611167,0.3585561,0.5072415],"study_design_scores_gemma":[0.0001551279,0.0001114642,0.005086321,0.0006344882,0.0002697847,0.000004985379,0.00001103576,0.0003468248,0.002859982,0.00001136289,0.990427,0.0000816164],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.5175384,0.3914963,0.0003590173,0.0144432,0.003090097,0.002178378,0.00003808659,0.0004413646,0.07041514],"genre_scores_gemma":[0.9675451,0.00520889,0.0005675483,0.001544571,0.0005876314,0.0002869298,0.00001099347,0.00002216364,0.02422618],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.6318709,"threshold_uncertainty_score":0.9975969,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4414450104","doi":"10.1159/000548606","title":"Surrogate Endpoints for Overall Survival in Advanced Hepatocelluar Carcinoma in the Era of Immunotherapy: A Trial Level Meta-Analysis","year":2025,"lang":"en","type":"article","venue":"Liver Cancer","topic":"Hepatocellular Carcinoma Treatment and Prognosis","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Ottawa Hospital; Princess Margaret Cancer Centre","funders":"","keywords":"Surrogate endpoint; Overall survival; Clinical endpoint; Progression-free survival; Endpoint Determination; Survival analysis","retraction":null,"screen_n_in":null,"score":{"opus":0.1833565736483253,"gpt":0.3373217047050122,"spread":0.1539651310566869,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007072053,0.0002429395,0.001251493,0.0003194752,0.00003940968,0.00001488045,0.0001900502,0.0001082766,0.0004064339],"category_scores_gemma":[0.00003522163,0.0001633047,0.001244965,0.0009200339,0.000050916,0.00007534435,0.00002620351,0.0002135605,0.000001992365],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001525883,"about_ca_system_score_gemma":0.0002461002,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.006473412,"about_ca_topic_score_gemma":0.004506005,"domain_scores_codex":[0.998201,0.0002618107,0.0005576285,0.0003790891,0.0002912149,0.0003092231],"domain_scores_gemma":[0.9988721,0.0003908193,0.0001449236,0.0004525805,0.0001044247,0.00003513952],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.02852551,0.0007442322,0.9281346,0.0001831375,0.03215377,0.00009154916,0.002381318,0.00005547837,0.0008670684,0.0004456342,0.0001115858,0.006306168],"study_design_scores_gemma":[0.1689018,0.001542764,0.6613477,0.0001324593,0.1326985,0.000002532569,0.0005825933,0.01024033,0.01860321,0.0006842933,0.004586725,0.0006771578],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9802105,0.0151933,0.0001328048,0.001208946,0.0001465951,0.002492774,0.00017371,0.00001074174,0.0004306029],"genre_scores_gemma":[0.9962485,0.0005810439,0.0003655622,0.0004774421,0.00004151667,0.001433886,0.0000588081,0.00001764022,0.0007756073],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.2667868,"threshold_uncertainty_score":0.9785905,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2106822989","doi":"10.1007/978-1-4020-9804-8_7","title":"Intraoperative Magnetic Resonance Imaging for Radiofrequency Ablation of Hepatic Tumors","year":2009,"lang":"en","type":"book-chapter","venue":"Liver Cancer","topic":"Hepatocellular Carcinoma Treatment and Prognosis","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"University of Calgary","funders":"","keywords":"Medicine; Debulking; Radiofrequency ablation; Magnetic resonance imaging; Radiology; Ablation; Interventional magnetic resonance imaging; Cancer","retraction":null,"screen_n_in":null,"score":{"opus":0.03694870924908961,"gpt":0.2508398812122156,"spread":0.213891171963126,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00008119152,0.0003129091,0.0005871811,0.0001420952,0.00005113847,0.00001167363,0.00007954078,0.0001408035,0.001046195],"category_scores_gemma":[0.00001408508,0.0002829252,0.0002405614,0.0000459177,0.00009724283,0.0001111947,0.00001252971,0.0001703064,0.00001732084],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002977877,"about_ca_system_score_gemma":0.0002502296,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001719525,"about_ca_topic_score_gemma":0.00003071877,"domain_scores_codex":[0.9987717,0.00001462837,0.0003800919,0.0003670062,0.0002530933,0.000213527],"domain_scores_gemma":[0.9991744,0.00005885176,0.0001880407,0.0002553952,0.000237029,0.00008633611],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.000354833,0.00006175697,0.04055679,0.0006002128,0.0001271031,0.0002399309,0.0009424043,0.000001154549,0.000551675,0.01196526,0.001208948,0.94339],"study_design_scores_gemma":[0.0155544,0.007094842,0.06062334,0.01898698,0.009765412,0.0002342157,0.00008182975,0.02258789,0.02121895,0.02822934,0.8121675,0.003455325],"study_design_candidate":"design_other","study_design_consensus":null,"genre_codex":"review","genre_gemma":"empirical","genre_scores_codex":[0.01288665,0.6721964,0.0004090315,0.001088691,0.0004374286,0.006162587,0.0006327712,0.0001375132,0.3060489],"genre_scores_gemma":[0.5292595,0.01976258,0.004963358,0.0009204246,0.00107345,0.0004965563,0.0005010181,0.0001991434,0.4428239],"genre_candidate":"other","genre_consensus":null,"teacher_disagreement_score":0.9399346,"threshold_uncertainty_score":0.9999623,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null}]}